Subchapter Lead, Head of Pathology

Roche•Tucson, AZ

6d•$255,900 - $475,300•Onsite

About The Position

At Roche, we are committed to creating a healthier future by advancing science and ensuring access to healthcare. As the Subchapter Lead in Clinical Development, Head of Pathology, you will lead a world-class team of pathologists at our Tucson, AZ campus. This role involves providing strategic and scientific leadership while overseeing pathology operations that support over 100 new and existing product development initiatives and enhancements annually. Your team will be instrumental in developing innovative diagnostics for precision medicine and targeted cancer therapies, working with cutting-edge technologies to transform patient care globally. This is an opportunity to mentor, inspire, and engage hands-on with leading-edge technologies.

Requirements

MD with US Board Certification in Anatomic Pathology.
10+ years of people management and leadership within a pharmaceutical, diagnostics, or major academic or medical center environment.
Deep expertise in oncology pathology and hands-on experience with tissue-based biomarkers (IHC, ISH, Multiplex).
Strong familiarity with development processes including digital pathology workflows, image analysis tools, Clinical Case and CAP/CLIA workflows, and CDx development.
Excellent communication, negotiation, and stakeholder management skills—ability to translate complex pathology findings to non-clinical teams.

Responsibilities

Direct, mentor, and foster the professional growth of a highly specialized team of pathologists and 6-7 team leaders.
Drive a culture of innovation, collaboration, and continuous learning.
Provide medical oversight for day-to-day Path Lab activities.
Serve as the pathology subject matter expert within the Companion Diagnostics & Oncology business unit, ensuring scientific rigor and clinical relevance in all assay development programs.
Guide the team in the development, validation, and implementation of complex assays utilizing top-tier technologies including: Immunohistochemistry (IHC) and in situ hybridization (ISH), Immunofluorescence (IF) and Multiplex assays, Digital Pathology and AI-driven image analysis.
Partner closely with life science companies, clinical trial teams, regulatory bodies, and internal R&D stakeholders.
Stay ahead of industry trends and emerging pathology technologies to maintain Roche’s position as the market leader in companion diagnostics and oncology.